East Asia expert opinion on treatment initiation for chronic hepatitis B-Reference-Cited by-同舟云学术

East Asia expert opinion on treatment initiation for chronic hepatitis B

Published:2020-09-20 Issue: Volume: Page:
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment. Pharmacol. Ther.

Author:

Kao Jia-Horng¹^ORCID,Hu Tsung-Hui²^ORCID,Jia Jidong³^ORCID,Kurosaki Masayuki⁴^ORCID,Lim Young-Suk⁵^ORCID,Lin Han-Chieh¹,Sinn Dong Hyun⁵^ORCID,Tanaka Yasuhito⁶^ORCID,Wai-Sun Wong Vincent⁷^ORCID,Yuen Man-Fung⁷^ORCID

Affiliation:

1. Taipei Taiwan

2. Kaohsiung Taiwan

3. Beijing Mainland China

4. Tokyo Japan

5. Seoul South Korea

6. Kumamoto Japan

7. Hong Kong SAR, China

Funder

Advancing Clinical Treatment - Liver Disease (ACT-LD) Taiwan.

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/apt.16097/fullpdf

Reference51 articles.

1. Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis;Lok;Hepatology,2016

2. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance;Terrault;Hepatology,2018

3. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection;European Association for the Study of the Liver;J Hepatol,2017

4. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update;Sarin;Hepatol Int,2016

5. Asian consensus recommendations on optimizing the diagnosis and initiation of treatment of hepatitis B virus infection in resource-limited settings;Gane;J Viral Hepat,2020

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk predictive model for the development of hepatocellular carcinoma before initiating long‐term antiviral therapy in patients with chronic hepatitis B virus infection;Journal of Medical Virology;2024-08-29

2. Significant liver histological change is common in HBeAg-positive chronic hepatitis B with normal ALT;BMC Infectious Diseases;2024-07-23

3. Improvement in renal function after switching from entecavir to tenofovir alafenamide in chronic hepatitis B patients with low estimated glomerular filtration rates;2024-06-25

4. Lower HBV DNA level is associated with more severe liver fibrosis in HBeAg-positive chronic hepatitis B with normal alanine transaminase;Virology Journal;2024-06-04

5. Clinical outcomes of treatment-naïve HBeAg-negative patients with chronic hepatitis B virus infection with low serum HBsAg and undetectable HBV DNA;Emerging Microbes & Infections;2024-04-16